GlassScriptPhysician profile
Qamar U Arfeen
NPI 1295738649
$5,057.12
in general payments reported to CMS, 2019-2025
30 companies · $614 in 2025
The $614 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $988 · 2021: $725 · 2022: $438 · 2023: $806 · 2024: $616 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,035.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $979.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Actelion Pharmaceuticals US, INC. | $608.56 | 2019-2023 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $565.97 | 2019-2022 | |
| Insmed, INC. | $538.42 | 2023-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $440.17 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Genzyme Corporation | $251.68 | 2019-2025 | |
| Philips North America LLC | $234.44 | 2019-2023 | |
| Pfizer INC. | $167.32 | 2020-2021 | |
| Mylan Specialty L.P. | $151.43 | 2020-2021 | |
| Inspire Medical Systems, INC. | $150.67 | 2023-2025 | Inspire |
| United Therapeutics Corporation | $122.79 | 2022 | |
| Genentech USA, INC. | $111.65 | 2019-2020 | |
| Amgen INC. | $107.54 | 2021-2023 | Tezspire |
| Janssen Pharmaceuticals, INC | $87.94 | 2020-2021 | |
| Ethicon US, LLC | $78.57 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $48.95 | 2023 | |
| Merck Sharp & Dohme LLC | $48.53 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.74 | 2020-2021 | |
| Abbvie INC. | $42.11 | 2023-2024 | Avycaz |
| Viatris Specialty LLC | $39.46 | 2025 | Yupelri |
| Inogen, INC. | $36.41 | 2020-2024 | |
| Circassia INC. | $31.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.59 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $29.63 | 2023 | Dupixent |
| Verona Pharma, INC. | $25.20 | 2025 | Ohtuvayre |
| Melinta Therapeutics, LLC | $20.32 | 2021 | |
| Electromed, INC. | $18.21 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.17 | 2021 | |
| Pulmonx Corporation | $16.05 | 2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Boston Scientific Corporation | $13.60 | 2023 | Acquire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qamar Arfeen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.